Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Lobucavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 12/20 | 0.56 |
| ▸ | PNP | P00491 | 3/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lobucavir SCHEMBL457256 | 1.00 | HPRT1 (0.56) | HPRT1PNPADORA3NT5EPOLB | |
| Lobucavir SCHEMBL9615451 | 0.96 | HPRT1 (0.53) | HPRT1PNPADORA3 | |
| Lobucavir SCHEMBL7699733 | 0.96 | HPRT1 (0.53) | HPRT1PNPADORA3 | |
| Lobucavir SCHEMBL5990162 | 0.96 | HPRT1 (0.53) | HPRT1PNPADORA3 | |
| Lobucavir SCHEMBL418430 | 0.96 | HPRT1 (0.53) | HPRT1PNPADORA3 | |
| Lobucavir SCHEMBL15630215 | 0.96 | HPRT1 (0.53) | HPRT1PNPADORA3 | |
| Lobucavir SCHEMBL598707 | 0.96 | HPRT1 (0.53) | HPRT1PNPADORA3 | |
| Lobucavir SCHEMBL9615453 | 0.96 | HPRT1 (0.53) | HPRT1PNPADORA3 | |
| Lobucavir SCHEMBL51918 | 0.96 | HPRT1 (0.53) | HPRT1PNPADORA3 | |
| Lobucavir SCHEMBL10460499 | 0.96 | HPRT1 (0.53) | HPRT1PNPADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100167268-A1 | SEROCONVERSION ASSAYS FOR DETECTING XENOTROPIC MURINE LEUKEMIA VIRUS-RELATED VIRUS | WHITTEMORE PETERSON INSTITUTE | 2010-07-01 | — | — | US | claimed |
| US-7611704-B2 | Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-03 | — | — | US | claimed |
| US-7511124-B2 | Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-03-31 | — | — | US | claimed |
| US-7455833-B2 | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-11-25 | — | — | US | claimed |
| US-7384909-B2 | Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-06-10 | — | — | US | claimed |
| US-20160311886-A1 | Constructs Binding to Phosphatidylserine and Their Use in Disease Treatment and Imaging | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2016-10-27 | — | — | US | disclosed |
| EP-2283868-B1 | Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer | UNIV TEXAS (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-1853631-B1 | Fc FUSION CONSTRUCTS BINDING TO PHOSPHATIDYLSERINE AND THEIR THERAPEUTIC USE | UNIV TEXAS (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2269656-B1 | Selected antibodies binding to aminophospholipids and their use in treatment, such as cancer | UNIV TEXAS (US) | 2014-08-20 | — | — | EP | disclosed |
| US-8653034-B2 | Compositions and methods comprising phosphatidylethanolamine-binding peptide derivatives | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130243756-A1 | Methods for Treating Diseases and HSV Using Antibodies to Aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130216999-A1 | METHODS AND KITS FOR THE DETECTION OF AN INFECTION IN SUBJECTS WITH LOW SPECIFIC ANTIBODY LEVELS | SMART BIOTECH LTD. (US) | 2013-08-22 | — | — | US | disclosed |
| US-7572448-B2 | Combined cancer treatment methods using selected antibodies to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-08-11 | — | — | US | disclosed |
| US-7384909-B2 | Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-06-10 | — | — | US | disclosed |
| US-7378386-B2 | Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-05-27 | — | — | US | disclosed |
| US-7247303-B2 | Selected antibody CDRs for binding to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-07-24 | — | — | US | disclosed |
| US-20050129696-A1 | Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM | 2005-06-16 | — | — | US | disclosed |
| US-20050031620-A1 | Combined cancer treatment methods using selected antibodies to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-02-10 | — | — | US | disclosed |
| US-20050025761-A1 | Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-02-03 | — | — | US | disclosed |
| US-20050002941-A1 | Combinations and kits for cancer treatment using selected antibodies to aminophospholipids | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2005-01-06 | — | — | US | disclosed |